Remplissage Versus Latarjet Coracoid Transfer for Recurrent Shoulder Instability
Launched by WESTERN UNIVERSITY, CANADA · Feb 27, 2018
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different surgical methods for treating patients with recurrent shoulder dislocation, also known as shoulder instability. The study aims to find out whether a technique called Remplissage, combined with a standard repair method, is as effective as another method called Latarjet, which involves transferring a piece of bone to stabilize the shoulder. This research is specifically looking at patients who have experienced more than one dislocation and have certain bone conditions in their shoulder, but without significant bone loss.
To be eligible for the trial, participants need to be over 14 years old, have had multiple shoulder dislocations, and show specific signs of bone damage on imaging tests. However, those with too much bone loss or other serious shoulder or medical issues cannot participate. If chosen for the trial, participants will undergo one of the two surgical procedures and will be followed for two years to monitor their recovery and shoulder stability. This study is currently recruiting participants of all genders, and it’s essential that they can communicate in either French or English.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • anterior shoulder instability (\>1 dislocation)
- • age \>14 years
- • evidence of a Hill-Sachs defect on MRI or CT,
- • \< 20% anteroposterior glenoid bone loss
- Exclusion Criteria:
- • \>20% anteroposterior glenoid bone loss
- • significant shoulder comorbidities (i.e., osteoarthritis, previous surgery other than previous instability), active joint or systemic infection, significant muscle paralysis, rotator cuff or Charcot's arthropathy,
- • significant medical comorbidity that may alter effectiveness of surgical intervention
- • major medical illness,
- • unable to speak French or English,
- • psychiatric illness that precludes informed consent,
- • unwilling to be followed for 2 years
About Western University, Canada
Western University, located in Canada, is a leading research institution committed to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and research teams to conduct high-quality studies that address pressing medical challenges. Western University is dedicated to fostering a culture of ethical research practices, ensuring participant safety, and generating impactful findings that contribute to evidence-based medicine and improve patient outcomes. Through its robust infrastructure and commitment to excellence, Western University plays a vital role in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Winnipeg, Manitoba, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials